NCT02396212View on ClinicalTrials.gov

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 7, 2015

Primary Completion Date

March 7, 2017

Study Completion Date

August 1, 2018

Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
BIOLOGICAL

Canakinumab

canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.

Trial Locations (7)

474 8710

Novartis Investigative Site, Ōbu

266-0007

Novartis Investigative Site, Chiba

920-8641

Novartis Investigative Site, Kanazawa

890 8520

Novartis Investigative Site, Kagoshima

232-8555

Novartis Investigative Site, Yokohama

236-0004

Novartis Investigative Site, Yokohama

989-3126

Novartis Investigative Site, Sendai

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY